2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(pyridin-3-yl)propanoic acid | 746672-88-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(pyridin-3-yl)propanoic acid
• 英文别名: Fmoc-beta-(3-pyridyl)-Ala-OH；2-(9H-fluoren-9-ylmethoxycarbonylamino)-3-pyridin-3-ylpropanoic acid
• CAS: 746672-88-8
• 化学式: C₂₃H₂₀N₂O₄
• 分子量: 388.423
• InChiKey: JQLPMTXRCLXOJO-UHFFFAOYSA-N

物化性质

• 沸点：
  645.6±55.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  88.5
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(pyridin-3-yl)propanoic acid 在 三氟乙酸 作用下， 生成 (2S)-2-[9H-fluoren-9- ylmethoxycarbonyl(methyl)amino]- 3-pyridin-3-ylpropanoic acid
  参考文献：
  名称：

  PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION

  摘要：

  Solid-phase synthesis of a peptide has a problem that a desired elongation reaction is prevented from proceeding by diketopiperazine and a 6-membered diamine skeleton compound formed when a protective group at the N-terminal is removed. The present inventors have found that when in production of a peptide by a solid-phase method, a peptide in which an amino group at the N-terminal is protected with a protective group having an Fmoc skeleton is treated in a specific solvent with a base having a pKa of 23 or more in acetonitrile as a conjugate acid, and a peptide chain is then elongated, it is possible to solve the problem described above.

  公开号：

  US20230391818A1
• 作为产物：
  描述：

  N-乙酰基-3-(3-吡啶)-丙氨酸 在 盐酸 、 水 、 碳酸氢钠 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 25.0h， 生成 2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-(pyridin-3-yl)propanoic acid
  参考文献：
  名称：

  Chemoenzymatic routes to enantiomerically pure 2-azatyrosine and 2-, 3- and 4-pyridylalanine derivatives

  摘要：

  Enantiomerically pure 2-, 3- or 4-pyridylalanine (pya) and 2-azatyrosine (azatyr) are known to present various biological activities. After incorporation into appropriate peptide sequences, these heterocyclic non natural alpha-amino acids could behave as new substrates or inhibitors of elastase from Pseudomonas aeruginosa. This enzyme is known to be involved in nosocomial infections and infections related to the cystic fibrosis disease. New efficient chemoenzymatic preparations of those compounds using alpha-chymotrypsin (alpha-CT) are presented.

  DOI：

  10.1007/s00726-010-0829-3

文献信息

• Derivatives of Amphotericin B
  申请人：Revolution Medicines, Inc.

  公开号：US20160304548A1

  公开（公告）日：2016-10-20

  Disclosed are derivatives of amphotericin B (AmB) characterized by improved therapeutic index compared to AmB. The AmB derivatives include C16 ureas, carbamates, and amides according to Formula (I); C3′-substituted C16 ureas, carbamates, and amides according to Formula (II); C16 acyls according to Formula (III); C2′epi-C16 ureas, carbamates, and amides according to Formula (IV); and C16 oxazolidinone derivatives according to Formula (V). Also disclosed are pharmaceutical compositions comprising the AmB derivatives, and therapeutic methods of using the AmB derivatives.

  披露了与AmB相比具有改善的治疗指数的Amphotericin B（AmB）衍生物。这些AmB衍生物包括根据公式（I）的C16脲、碳酸酯和酰胺；根据公式（II）的C3′-取代的C16脲、碳酸酯和酰胺；根据公式（III）的C16酰基；根据公式（IV）的C2′epi-C16脲、碳酸酯和酰胺；以及根据公式（V）的C16噁唑烷酮衍生物。还披露了包括这些AmB衍生物的药物组合物，以及使用这些AmB衍生物的治疗方法。
• [EN] PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII<br/>[FR] MACROCYCLES PEPTIDIQUES CONTRE ACINETOBACTER BAUMANNII
  申请人：HOFFMANN LA ROCHE

  公开号：WO2017072062A1

  公开（公告）日：2017-05-04

  The present invention provides compounds of formula (I) wherein X1 to X8 and R1 to R8 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.

  本发明提供了式（I）的化合物，其中X1至X8和R1至R8如本文所述，以及其药学上可接受的盐。此外，本发明涉及制备式（I）的化合物，包括它们的药物组合物以及它们作为治疗由鲍曼不动杆菌引起的疾病和感染的药物的用途。
• METHOD FOR SYNTHESIZING PEPTIDES IN CELL-FREE TRANSLATION SYSTEM
  申请人：Chugai Seiyaku Kabushiki Kaisha

  公开号：US20200040372A1

  公开（公告）日：2020-02-06

  An objective of the present invention is to provide methods of synthesizing peptides containing structurally diverse amino acids using cell-free translation systems, which can accomplish excellent translational efficiency as compared to conventional techniques (the conventional techniques being methods which involve preparing aminoacyl-tRNAs which do not have protecting groups outside the translation systems without using ARS, and then adding the prepared aminoacyl-tRNAs into translation systems). In the present invention, it was found that amino acid-containing peptides can be synthesized efficiently by protecting an amino acid linked to tRNA with an appropriate protecting group, and then performing the step of deprotecting the protecting group of the amino acid linked to tRNA and the step of peptide translation from a template nucleic acid in a cell-free translation system in parallel.

  本发明的一个目标是提供使用无细胞翻译系统合成含有结构多样的氨基酸的肽的方法，这些方法可以实现与传统技术相比出色的翻译效率（传统技术是指涉及在翻译系统外部准备没有保护基的氨酰-tRNA而不使用ARS的方法，然后将准备好的氨酰-tRNA添加到翻译系统中）。在本发明中，发现通过用适当的保护基保护与tRNA连接的氨基酸，然后并行进行去保护氨基酸与tRNA连接的保护基的步骤和从模板核酸进行肽翻译的步骤，可以高效地合成含有氨基酸的肽。
• [EN] GLUCAGON ANTAGONISTS/INVERSE AGONISTS<br/>[FR] ANTAGONISTES/AGONISTES INVERSES DU GLUCAGON
  申请人：NOVO NORDISK AS

  公开号：WO1999001423A1

  公开（公告）日：1999-01-14

  Non-peptide compounds comprising a central hydrazide motif and methods for the synthesis thereof. The compounds act to antagonize the action of the glucagon peptide hormone.

  非肽化合物包含一个中心肼基结构，并且其合成方法。这些化合物作用是拮抗胰高血糖素肽激素的作用。
• [EN] SOLID-PHASE SYNTHESIS METHOD FOR DEGARELIX<br/>[FR] PROCÉDÉ DE SYNTHÈSE EN PHASE SOLIDE DE DÉGARÉLIX<br/>[ZH] 一种地加瑞克的固相合成方法
  申请人：HYBIO PHARMACEUTICAL CO LTD

  公开号：WO2021103458A1

  公开（公告）日：2021-06-03

  提供了一种地加瑞克的固相合成方法，包括：1)肽树脂的偶联：按照Fmoc固相合成方法，逐个偶联氨基酸Fmoc-D-Ala-OH、Fmoc-Pro-OH、Fmoc-Lys(Boc,iPr)-OH、Fmoc-Leu-OH、Fmoc-D-4Aph(Cbm)-OH、Fmoc-4Aph(Hmb,Hor)-OH、Fmoc-Ser(tBu)-OH、Fmoc-D-3Pal-OH、Fmoc-D-4Cpa-OH以及Fmoc-D-2Nal-OH至固相载体上；2)肽树脂N端乙酰化；3)肽树脂裂解后获得地加瑞克粗肽。